glp-1 alcohol absorption study october 2025 Altimmune's Drug Reduces Heavy Drinking in Alcohol-Use Disorder Trial. Altimmune's pemvidutide achieved a statistically significant reduction in heavy drinking days compared to a placebo in a Phase 2 trial. This peptide GLP-1 drugs are already linked

Another real-world study, published in July 2024 by Prime Therapeutics, showed that 85% of patients were no longer taking GLP-1 drugs two years after starting treatment

Neurotransmitter Inhibitors Acetyl Hexapeptide-3 (Argireline) reduces acetylcholine release, smoothing expression lines

Together, these strategies synergize to advance the field from mechanistic investigation toward personalized therapeutics, opening new avenues for treating diseases such as cancer, fibrosis, and chronic inflammation ( Figure 6 )

Navigate Future Markets with Confidence: Insights from Spherical Insights LLP The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises

Journal of Clinical Pharmacy and Therapeutics , 45 (1), 134143